The abstract and complete content is available to be accessed on the web at:.. Aethlon Medical establishes ESI while a owned subsidiary wholly Aethlon Medical, Inc. announced today that it has established Exosome Sciences, Inc. as a wholly possessed subsidiary of the Company. Aethlon Medical, Inc. Will contribute into ESI all exosome-related patents and patents pending. Jim Joyce, Chief and Chairman Executive Officer of Aethlon Medical, Inc. Said, ‘The capability to reduce circulating exosomes would likely reverse immune suppression and boost individual responsiveness to both immunotherapy and chemotherapy, hence positioning ESI to take part in the $43 billion malignancy therapy market.Dr Vinay Tergaonkar, Principal Investigator at IMCB and the lead scientist for the scholarly research, said, ‘It is alarming that weight problems is an enormous risk factor for most ailments, including diabetes. Having identified this proteins, we are now a step closer towards removing one of these complications from people experiencing obesity.’ ‘The world is paying a whole lot of focus on diabetes. Every year, vast amounts of dollars are spent on metabolic illnesses and a big area of the expenditure goes to the medications for diabetes.